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We hypothesize that immune responses that develop fol-
lowing immunotherapy, particularly in patients with
objective responses, are directed against a wide range of
antigenic determinants. However, in the absence of auto-
logous tumor cells, monitoring is frequently limited to a
small number of well-defined tumor-associated antigens
(TAA) and underestimates the immune response.
Further, we hypothesize that the majority of antigens
expressed by HLA on tumor cells are short-lived proteins
(SLiPs and DRiPs), which are rapidly degraded by the
proteasome, bound to HLA and transported to the
tumor’s surface. To develop an antigen source to evaluate
this hypothesis in men with prostate cancer, gene expres-
sion datasets for prostate cancer (n=85) were compared
with several tumor cell lines. One cell line, UbiLT3, had
at least 1 overexpressed gene in common (avg 37.1 genes:
range 0-200, Z-score 2) with 98.9% of the prostate can-
cers, suggesting that UbiLT3 had TAA in common with
prostate cancer. Next UbiLT3 were cultured with proteo-
somal and lysosomal inhibitors to accumulate SLiPs and
DRiPs in autophagosomes (DRibbles/DRb), which were
harvested and used to monitor anti-tumor responses in
patients vaccinated with allogeneic prostate GVAX (PC3/
LNCaP). After one week of IVS with UbiLT3-DRb, we
observed UbiLT3-DRb-specific CD8 T-cell responses in
post-vaccine PBMC of 6/12 patients (range 2-22% of
CD8). No responses were seen in pre PBMC or healthy
donor controls. We could not induce T cells recognizing
normal kidney (NK) control DRb after 1-week IVS nor
could UbiLT3-DRb stimulated T cells recognize NK-DRb.
The difference between pre vs. post DRibble-specific
responses was highly significant (p=0.007). To rule out
qualitative differences between pre- and post-vaccine
antigen-presenting cells, UbiLT3-DRb stimulated CD11c+
cells were isolated from pre and post-vaccine PBMC and
were cultured with isolated non-stimulated pre- or post
vaccine T cells. Pre and post CD11c+ cells were equally
able to induce CD8 responses in post T cells but not pre
T cells (n=2). Our data show that vaccination with pros-
tate GVAX induced T cell responses that recognized
DRibbles from a cancer cell line that shared common
overexpressed genes, but not DRibbles from normal
kidney cells. Since no autologous tumors were isolated
from these patients, we are looking for ways to evaluate
the tumor-killing abilities of these T cells. Current studies
are examining this strategy in cancers where autologous
tumor cells are available.
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